Patent US4621049A successfully refreshed from Google Patents.
Patent US4668699A successfully refreshed from Google Patents.
US4668699A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel HMG-CoA reductase inhibitors
Assignee: Merck and Co Inc
•
Filing: 1985-08-05
•
Granted: 1987-05-26
•
Expires: 2005-08-05
Abstract
Abstract Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) or (II): <IMAGE> (I) <IMAGE> (II) wherein: n is 1 to 5; R is hydrogen or <IMAGE> R1 is hydrogen or methyl; R2 is hydrogen or methyl; and R3 is hydrogen, C1-5 alkyl or C1-5 alkyl substituted with a member of the group consisting of phenyl, dimethylamino, or acetylamino; and the dotted lines at a, b and c represent optional double bonds and pharmaceutically acceptable salts of the compounds (II) in which R3 is hydrogen are disclosed.
Inventors
- 👤 William F. Hoffman
- 👤 Robert L. Smith
- 👤 Edward Scolnick
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 08:09
CPC Classifications
C; C07; C07H; C07H9/00; C07D; C07D309/00; C07D309/16; C07D309/28; C07D309/30; A; A61; A61P; A61P3/00; A61P3/06; A61P43/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
43 words
A compound represented by the following general structural formula (I): ##STR17## wherein: n is 1 to 5; R is hydrogen R 1 is methyl; R 2 is hydrogen or methyl; and the dotted lines at a, b and c represent optional double bonds.
Claim 2
Dependent Claim
43 words
A compound represented by the following general structural formula (I): ##STR17## wherein: n is 1 to 5; R is hydrogen R 1 is methyl; R 2 is hydrogen or methyl; and the dotted lines at a, b and c represent optional double bonds.
Claim 3
Dependent Claim
16 words
A compound of claim 1 wherein n is 1 to 3 and R 2 is methyl.
Claim 4
Dependent Claim
31 words
A compound of claim 2 wherein one of the dotted lines at a, b or c represents a double bond or the dotted lines at a anc c represent double bonds.
Claim 5
Dependent Claim
16 words
A compound of claim 3 wherein the dotted line at a and c represent double bonds.
Claim 6
Dependent Claim
8 words
A compound of claim 4 which is 6(R)-[2-[8(S)-(2,2-dimethyl-4-hydroxybutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.
Claim 7
Dependent Claim
8 words
A compound of claim 4 which is 6(R)-[2-[8(S)-(2,2-dimethyl-5-hydroxypentanoyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.
Claim 8
Dependent Claim
8 words
A compound of claim 4 which is 6(R)-[2-[8(S)-(2,2-dimethyl-3-hydroxypropionyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.
Claim 9
Dependent Claim
22 words
A hypocholesterolemic, hypolipidemic pharmaceutical composition comprising a nontoxic therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
30 words
A method of inhibiting cholesterol biosynthesis comprising the administration to a warm blooded mammals in need of such treatment a nontoxic therapeutically effective amount of a compound of claim 1.
Claim 11
Dependent Claim
17 words
A pharmaceutical composition of claim 8 wherein n is 1 to 3 and R 2 is methyl.
Claim 12
Dependent Claim
32 words
A pharmaceutical composition of claim 10 wherein one of the dotted lines at a, b or c represents a double bond or the dotted lines at a and c represent double bonds.
Claim 13
Dependent Claim
17 words
A pharmaceutical composition of claim 11 wherein to dotted lines at a and c represent double bonds.
Claim 14
Dependent Claim
21 words
A pharmaceutical composition of claim 12 wherein the therapeutically active ingredient is selected from (a) 6(R)-[2-[8(S)-(2,2-dimethyl-4-hydroxybutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one; (b) 6(R)-[2-[8(S)-(2,2-dimethyl-5-hydroxypentanoyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one; and (c) 6(R)-[2-[8(S)-(2,2-dimethyl-3-hydroxypropionyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.
Claim 15
Dependent Claim
16 words
A method of claim 9 wherein n is 1 to 3 and R 2 is methyl.
Claim 16
Dependent Claim
31 words
A method of claim 10 wherein one of the dotted lines at a, b or c represents a double bond or the dotted lines at a and c represent double bonds.
Claim 17
Dependent Claim
16 words
A method of claim 15 wherein the dotted lines at a and c represent double bonds.
Claim 18
Dependent Claim
20 words
A method of claim 16 wherein the therapeutically active ingredient is selected from (a) 6(R)-[2-[8(S)-(2,2-dimethyl-4-hydroxybutyryloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronapthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one; (b) 6(R)-[2-[8(S)-(2,2-dimethyl-5-hydroxypentanoyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one; and (c) 6(R)-[2-[8(S)-(2,2-dimethyl-3-hydroxypropionyloxy)-2(S),6(R)-dimethyl-1,2,6,7,8,8a(R)-hexahydronaphthyl-1(S)]ethyl]-4(R)-hydroxy-3,4,5,6-tetrahydro-2H-pyran-2-one.
References Cited (Backward Citations)
US4346227A
Cited
US4410629A
Cited
US4448979A
Cited
US4376863A
Cited
US4517373A
Cited
EP0094443A1
Cited
JPS59122483A
Cited
EP0137445A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-25 | 1990-11-24 | 1991-05-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-25 | 1994-11-24 | 1995-05-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-25 | 1998-11-24 | 1999-05-26 | $7700.00 | Window Closed / Lapsed |